Reata Pharmaceuticals Inc RETA

NAS: RETA | ISIN: US75615P1030   25/09/2023
172,36 USD (+0,02%)
(+0,02%)   25/09/2023
Grafiek Reata Pharmaceuticals Inc Grafiek Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc in het nieuws

8 januari 2024 · Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock · Persbericht

18 maart 2023 · REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA · Persbericht

17 februari 2022 · RETA LAWSUIT ALERT: Levi & Korsinsky Notifies Reata Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

16 februari 2022 · RETA Investors Have Opportunity to Lead Reata Pharmaceuticals, Inc. Securities Fraud Lawsuit · Persbericht

10 februari 2022 · RETA LAWSUIT ALERT: Levi & Korsinsky Notifies Reata Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

4 februari 2022 · REATA PHARMACEUTICALS, INC. (NASDAQ: RETA) SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (NASDAQ: RETA) · Persbericht

2 februari 2022 · RETA LAWSUIT ALERT: Levi & Korsinsky Notifies Reata Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

31 januari 2022 · Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA) · Persbericht

13 januari 2022 · Reata Pharmaceuticals SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reata Pharmaceuticals, Inc. - RETA · Persbericht

6 januari 2022 · REATA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reata Pharmaceuticals, Inc. - RETA · Persbericht

Profiel Reata Pharmaceuticals Inc

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: reatapharma.com

Hoofdzetel: Plano, Texas vlag Verenigde Staten

CEO: J. Warren Huff

Werknemers: 372

Aandelen Reata Pharmaceuticals Inc

Effecten: 33,59 miljoen

Winst per aandeel (12 maand):  PLUS

Mijn selecties